Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF N486_P490del Trametinib pancreatic ductal adenocarcinoma sensitive detail...
ATM R3008C Fluorouracil + Oxaliplatin + Veliparib pancreatic ductal adenocarcinoma no benefit detail...
ATM T2333Nfs*40 Fluorouracil + Oxaliplatin + Veliparib pancreatic ductal adenocarcinoma no benefit detail...
BRAF N486_P490del LY3009120 pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF N486_P490del LY3009120 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
BRAF V600E Cobimetinib + Gemcitabine + Nab-paclitaxel pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF V600E Trametinib + Vemurafenib pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF V600E Ulixertinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
FGFR2 rearrange Erdafitinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF N486_P490del Dabrafenib + Trametinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF N486_P490del Ulixertinib pancreatic ductal adenocarcinoma sensitive detail...
BRAF N486_P490del Binimetinib pancreatic ductal adenocarcinoma sensitive detail...
BRAF N486_P490del SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
BRAF N486_P490del Sorafenib pancreatic ductal adenocarcinoma sensitive detail...
BRAF N486_P490del LXH 254 pancreatic ductal adenocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01647828 Phase Ib/II Nab-paclitaxel Gemcitabine Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Completed USA 0
NCT02042378 Phase II Rucaparib A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed USA 1
NCT02101021 Phase II Gemcitabine + Nab-paclitaxel Momelotinib Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT02109445 Phase II Gemcitabine + Nab-paclitaxel Nirogacestat Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated USA 0
NCT02241187 Phase I Cetuximab + PEGPH20 Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection Completed USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02289898 Phase II Demcizumab + Gemcitabine + Nab-paclitaxel Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed USA | GBR | ESP | CAN | BEL | AUS 0
NCT02362048 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02501902 Phase I Nab-paclitaxel + Palbociclib Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Completed USA | ESP 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02583477 Phase Ib/II AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed USA | GBR 0
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Recruiting USA 0
NCT02672917 Phase I MVT-5873 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Recruiting USA 0
NCT02705196 Phase Ib/II Atezolizumab + Gemcitabine + LOAd703 + Nab-paclitaxel Gemcitabine + LOAd703 + Nab-paclitaxel LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer Recruiting USA 0
NCT02732938 Phase I Gemcitabine + Nab-paclitaxel + PF-04136309 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) Terminated USA 0
NCT02754726 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT02810418 Phase Ib/II LMB-100 LMB-100 + Nab-paclitaxel Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Completed USA 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02879318 Phase II Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma Active, not recruiting CAN 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02921022 Phase 0 Gemcitabine + Nab-paclitaxel + PEGPH20 Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Active, not recruiting USA 0
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Completed USA 0
NCT02978547 Phase II Metformin The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) Unknown status CAN 0
NCT02981342 Phase II Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Completed USA | GBR | FRA | ESP | BEL | AUS 2
NCT02993731 Phase III Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 11
NCT03038477 Phase II Durvalumab A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection Withdrawn USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03118349 Phase I MVT-1075 + MVT-5873 Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy Terminated USA 0
NCT03193190 Phase Ib/II Atezolizumab + BKT140 Fluorouracil + Gemcitabine + Leucovorin + Nab-paclitaxel + Oxaliplatin + Pembrolizumab Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Active, not recruiting USA | ESP | DEU 2
NCT03264404 Phase II Azacitidine + Pembrolizumab Azacitidine and Pembrolizumab in Pancreatic Cancer Active, not recruiting USA 0
NCT03412799 Phase I Gemcitabine + Nab-paclitaxel + SBP-101 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Completed USA | AUS 0
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03415854 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD) Completed USA 0
NCT03425279 Phase Ib/II Mecbotamab Vedotin CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA 2
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Terminated USA | FRA | ESP 0
NCT03450018 Phase Ib/II Gemcitabine + SLC-0111 A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) Recruiting CAN 0
NCT03496662 Phase Ib/II Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Active, not recruiting USA 0
NCT03592888 Phase I mDC3/8-KRAS vaccine DC Vaccine in Pancreatic Cancer Active, not recruiting USA 0
NCT03608631 Phase I iExosomes iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation Active, not recruiting USA 0
NCT03610490 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT03634332 Phase II PEGPH20 + Pembrolizumab Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Unknown status USA 0
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Terminated USA | BEL 1
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated USA 0
NCT03682289 Phase II Ceralasertib + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting USA 0
NCT03727880 Phase II Defactinib + Pembrolizumab Pembrolizumab Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | GBR | FRA | ESP 2
NCT03806309 Phase II OSE 2101 Nivolumab + OSE 2101 Fluorouracil + Irinotecan + Leucovorin Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM) Recruiting FRA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03871959 Phase I Pembrolizumab + Xevinapant Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) Completed FRA 0
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT03979066 Phase II Atezolizumab Atezolizumab + PEGPH20 Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) Terminated USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP 0
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Suspended USA 0
NCT04117958 Phase I AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers Terminated USA | FRA | ESP | DEU | AUT 4
NCT04161755 Phase I Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery Active, not recruiting USA 0
NCT04229004 Phase III Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04257448 Phase Ib/II Gemcitabine + Nab-paclitaxel + Romidepsin Azacitidine + Gemcitabine + Nab-paclitaxel Azacitidine + Gemcitabine + Nab-paclitaxel + Romidepsin Gemcitabine + Nab-paclitaxel Durvalumab + Lenalidomide Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION) Active, not recruiting DEU 0
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Withdrawn CAN 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04431258 Phase Ib/II ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) Recruiting USA | FRA | ESP 1
NCT04477343 Phase I Nivolumab + SX-682 A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT04493060 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT04536077 Phase II CDX-1140 + CDX-301 CDX-1140 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients Terminated USA 0
NCT04581343 Phase I Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) Active, not recruiting USA 0
NCT04659603 Phase II SAR408701 Gemcitabine + SAR408701 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) Active, not recruiting USA | ESP 8
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | BEL 3
NCT04752696 Phase II Fluorouracil + Leucovorin + Liposomal irinotecan + Onvansertib Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT04753879 Phase II Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Recruiting USA 0
NCT04809766 Phase I Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT04853017 Phase Ib/II ELI-002 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) Active, not recruiting USA 0
NCT04887805 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer Recruiting USA 0
NCT04888312 Phase Ib/II Fluorouracil + Irinotecan + JNJ-64457107 + Leucovorin + Oxaliplatin Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1) Active, not recruiting FRA | ESP | BEL 0
NCT04892017 Phase Ib/II DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Recruiting USA 0
NCT04900818 Phase I TJ033721 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT04907851 Phase II Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) Completed GBR | AUS 0
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Recruiting 1
NCT04935359 Phase III Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Recruiting USA | CAN | BEL 4
NCT04975217 Phase I Fecal microbiota Fecal Microbial Transplants for the Treatment of Pancreatic Cancer Recruiting USA 0
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | FRA | ESP | BEL | AUS 5
NCT04989387 Phase I INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 Study of INCA 0186 in Subjects With Advanced Solid Tumors Active, not recruiting USA | GBR | ESP | BEL | AUT 1
NCT04990037 Phase I Fluorouracil + Irinotecan + Leucovorin + Nidanilimab + Oxaliplatin A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (CAPAFOUR) Completed FRA | ESP 0
NCT05031494 Phase II Toripalimab-tpzi + YH003 Gemcitabine + Nab-paclitaxel + Toripalimab-tpzi + YH003 A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers Active, not recruiting USA | AUS 0
NCT05042128 Phase II Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) Active, not recruiting AUS 1
NCT05052723 Phase II Cabozantinib + Pembrolizumab Cabozantinib and Pembrolizumab in Metastatic Pancreas Active, not recruiting USA 0
NCT05055323 Phase I Pyrvinium A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer Recruiting USA 0
NCT05074472 Phase Ib/II ZB131 A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors Completed USA 0
NCT05121038 Phase Ib/II CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) Recruiting USA 0
NCT05254171 Phase II Gemcitabine + Nab-paclitaxel + SBP-101 Gemcitabine + Nab-paclitaxel Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 1
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 3
NCT05307874 Phase Ib/II Aldesleukin + ICT01 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) Recruiting FRA 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 17
NCT05442749 Phase II Niraparib Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) Recruiting FRA 0
NCT05458219 Phase I IBI343 A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Recruiting AUS 0
NCT05494866 Phase I Cobicistat + Gemcitabine + Nab-paclitaxel A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify) Recruiting DEU 0
NCT05498597 Phase I AMT-151 AMT-151 in Patients With Selected Advanced Solid Tumours Recruiting AUS 1
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT05546853 Phase I Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1) Recruiting FRA 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05558982 Phase II Pembrolizumab + Talabostat mesylate BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC) Recruiting USA 0
NCT05585320 Phase Ib/II IMM-1-104 A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05605522 Phase I 225Ac-FPI-2059 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours Recruiting USA | AUS 0
NCT05607953 Phase I Pembrolizumab + SD-101 Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma Recruiting USA 0
NCT05630183 Phase II Gemcitabine + Nab-paclitaxel Botensilimab + Gemcitabine + Nab-paclitaxel A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Recruiting USA 0
NCT05631574 Phase I BMF-219 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Recruiting USA 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05669482 Phase Ib/II Defactinib + Gemcitabine + Nab-paclitaxel + RO5126766 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205) Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05821556 Phase II Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients Recruiting ITA | ESP 0
NCT05846516 Phase I ATP150 + ATP152 + VSV-GP154 ATP150 + ATP152 + Ezabenlimab + VSV-GP154 A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) Recruiting USA 1
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05875168 Phase Ib/II DS-3939a First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Recruiting USA 1
NCT05922930 Phase Ib/II TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer Recruiting USA 0
NCT05968326 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003) Recruiting USA 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05977322 Phase I 177Lu-FF58 A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Recruiting ESP 3
NCT05983133 Phase I SGN-EGFRd2 A Study of SGN-EGFRd2 in Advanced Solid Tumors Recruiting USA 0
NCT05984602 Phase I Canakinumab + Gemcitabine + Nab-paclitaxel + Tislelizumab A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer Recruiting USA 0
NCT06015724 Phase II Daratumumab + Nivolumab + QS21 + TG01 Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX) Recruiting USA 0
NCT06024174 Phase Ib/II Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors Recruiting USA | ITA | FRA | ESP | BEL | AUS 2
NCT06026410 Phase I Cabozantinib + KO-2806 KO-2806 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) Recruiting USA 0
NCT06048484 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegfilgrastim AB680 + Etrumadenant + Zimberelimab AB680 + Zimberelimab Zimberelimab Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc) Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06059001 Phase I Gemcitabine + Nab-paclitaxel + OMO-103 Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02) Recruiting ESP 0
NCT06060405 Phase II Durvalumab + Oleclumab Durvalumab and Oleclumab in Resectable PDAC (DORA) Recruiting CAN 0
NCT06069778 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + MVT-5873 + Oxaliplatin Safety, Tolerability, and Efficacy of mFOLFIRINOX +/- BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma Recruiting USA 0
NCT06076837 Phase I Balstilimab + Botensilimab + Celecoxib + Chloroquine phosphate + Cisplatin + Gemcitabine + Nab-paclitaxel The Seven Trial: Exploiting the Unfolded Protein Response Not yet recruiting USA 0
NCT06084481 Phase I ABBV-400 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting USA 2
NCT06105021 Phase Ib/II AFNT-211 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor Recruiting USA 0
NCT06131840 Phase I SGN-CEACAM5C A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06141031 Phase Ib/II C188-9 Phase 1/2 Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer Recruiting USA 0
NCT06179160 Phase I Cetuximab + INCB161734 + Retifanlimab INCB161734 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Recruiting USA | AUS 0
NCT06203821 Phase I NP137 Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer Not yet recruiting USA 0
NCT06205849 Phase I JNJ-64457107 Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer Not yet recruiting USA 0
NCT06206876 Phase I FL118 FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Not yet recruiting USA 0
NCT06219941 Phase II AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Recruiting USA | GBR | ESP | CAN | AUS 7
NCT06255665 Phase I JNJ-79032421 A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Recruiting ESP 0